Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$27.11 USD
-0.49 (-1.78%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $27.09 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARS 27.11 -0.49(-1.78%)
Will TARS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
Other News for TARS
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Barclays Remains a Buy on Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript